Erasca, a clinical-stage oncology company, priced an upsized public offering of 31.4 million shares at $17.50 each, raising approximately $550 million before expenses. The funds will support research and development of therapies targeting RAS/MAPK pathway-driven cancers, as well as general corporate purposes. The offering is expected to close on July 15, 2026, with underwriters having an option to buy additional shares. This capital raise aims to advance Erasca's mission to develop precision cancer treatments.
Madonna returned to New York City to celebrate her No.1 album Confessions II with CLUB CONFESSIONS, a nightlife event co-hosted by MISTR that highlights dance music, queer culture, and HIV prevention. The event featured performances by Madonna and co...
Autonomix Medical has entered a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants, raising approximately $2.6 million. The investor will purchase 428,731 shares at a reduced price of $6.00 per share. In ...
Edelson Lechtzin LLP is investigating Richemont for allegedly raising prices on luxury goods due to tariffs imposed under the Trump administration and failing to refund customers after the U.S. Supreme Court ruled those tariffs unlawful in February 2...
Binance's latest proof-of-reserves report shows customer Bitcoin holdings increased by 1.22% in June, adding 7,715 BTC to reach about 640,000 BTC. Meanwhile, Ethereum holdings fell by 1.41% and Tether balances dropped by 1.51%. These changes reflect ...
VEON Ltd.'s subsidiary Jazz International Holding Limited has acquired a 76.33% controlling stake in TPL Insurance Limited, a leading digital insurer in Pakistan, for about USD 16.4 million. This acquisition integrates insurance into VEON's digital e...
